EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme

David J Jackson, Girolamo Pelaia, Benjamin Emmanuel, Trung N Tran, David Cohen, Vivian H Shih iD, Anat Shavit, Douglas Arbetter, Rohit Katial, Adrian Paul J Rabe iD, Esther Garcia Gil, Marisa Pardal und 7 weitere

European Respiratory Journal · 2024-07 · 64 (1) · 2301521

DOI: 10.1183/13993003.01521-2023 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Respiratory Journal, online erschienen am 04.04.2024. Verfasst von David J Jackson und 18 weiteren Autor:innen. Beteiligte Einrichtung: Guy's Severe Asthma Centre, Guy's and Thomas' NHS Trust, London, UK david.jackson@gstt.nhs.uk. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Anti-Asthmatic Agents. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pivotal phase 3 trials and real-world studies have demonstrated benralizumab's overall efficacy and safety in severe eosinophilic asthma (SEA). Additional large-cohort data are needed to confirm its real-world effectiveness in SEA according to previous biologic use and key baseline characteristics important for treatment selection.

Methods

XALOC-1 is a large, multinational, retrospective, observational, real-world study programme of benralizumab in adults with SEA. This 48-week integrated analysis assessed annualised exacerbation rate (AER), maintenance oral corticosteroid (mOCS) use, asthma symptom control and lung function during a 12-month baseline period and up to 48 weeks after benralizumab initiation. Subgroup analyses were based on previous biologic use and key baseline clinical characteristics (mOCS use, blood eosinophil count, exacerbation history, age at asthma diagnosis, fractional exhaled nitric oxide level and presence of atopy and chronic rhinosinusitis with nasal polyps).

Results

Out of 1002 patients analysed, 380 were biologic-experienced. At week 48, 71.3% were exacerbation-free ( versus 17.2% at baseline); relative reduction in AER was 82.7% overall and 72.9% in biologic-experienced patients; rates were maintained across all key clinical characteristic subgroups. Of patients using mOCS at baseline (n=274), 47.4% (130 out of 274) eliminated their use by week 48; the mean reduction from baseline in daily dose was 51.2% and, notably, 34.9% in biologic-experienced patients (n=115). Clinically significant improvements in asthma symptom control and lung function were observed.

Conclusion

In this large, real-world programme, SEA patients treated with benralizumab had substantial improvements in clinical outcomes irrespective of previous biologic use and key clinical characteristics important to therapeutic decision-making in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAntibodies, Monoclonal, HumanizedAnti-Asthmatic AgentsHumansMaleFemaleMiddle AgedRetrospective StudiesAdultTreatment OutcomeAgedEosinophilsAdrenal Cortex HormonesEosinophilia

Substanzen

benralizumabAntibodies, Monoclonal, HumanizedAnti-Asthmatic AgentsAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Guy's Severe Asthma Centre, Guy's and Thomas' NHS Trust, London, UK david.jackson@gstt.nhs.uk.
  • School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Department of Health Sciences, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
  • AstraZeneca, Gaithersburg, MD, USA.
  • AstraZeneca, Cambridge, UK.
  • AstraZeneca, Boston, MA, USA.

ORCID-Profile: Vivian H Shih, Adrian Paul J Rabe, Cláudia Chaves Loureiro

Förderung

  • AstraZeneca

Zitieren

APA

Jackson, D. J., Pelaia, G., Emmanuel, B., Tran, T. N., Cohen, D., Shih, V. H., Shavit, A., Arbetter, D., Katial, R., Rabe, A. P. J., Garcia Gil, E., Pardal, M., Nuevo, J., Watt, M., Boarino, S., Kayaniyil, S., Chaves Loureiro, C., Padilla-Galo, A., & Nair, P. (2024). Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme. European Respiratory Journal, 64(1), 2301521. https://doi.org/10.1183/13993003.01521-2023

Vancouver

Jackson DJ, Pelaia G, Emmanuel B, Tran TN, Cohen D, Shih VH, et al. Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme. European Respiratory Journal. 2024;64(1):2301521. doi:10.1183/13993003.01521-2023

BibTeX
@article{Jackson2024,
  author = {Jackson, David J and Pelaia, Girolamo and Emmanuel, Benjamin and Tran, Trung N and Cohen, David and Shih, Vivian H and Shavit, Anat and Arbetter, Douglas and Katial, Rohit and Rabe, Adrian Paul J and Garcia Gil, Esther and Pardal, Marisa and Nuevo, Javier and Watt, Michael and Boarino, Silvia and Kayaniyil, Sheena and Chaves Loureiro, Cláudia and Padilla-Galo, Alicia and Nair, Parameswaran},
  title = {Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme},
  journal = {European Respiratory Journal},
  year = {2024},
  volume = {64},
  number = {1},
  pages = {2301521},
  doi = {10.1183/13993003.01521-2023}
}
Kostenlos starten →